Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on August 8, 2023. The filing announces the release of earnings results for the second quarter ended July 1, 2023. The company's ordinary shares and various notes are registered on the New York Stock Exchange.
Key Financial Metrics
This Form 8-K serves as a notification of the earnings release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The detailed financial figures are contained in the attached press release (Exhibit 99.1), which is not included in the provided text.
Material Changes and Non-GAAP Adjustments
The filing details the specific items excluded from the company's non-GAAP financial measures to facilitate comparability. For the three and six months ended July 1, 2023, adjustments included:
- Amortization expense related to acquired intangible assets.
- Restructuring charges and termination benefits.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Unusual litigation costs.
- (Gain) loss on investment securities and divestitures.
- Milestone payments received related to royalty rights.
- Non-GAAP tax adjustments and foreign currency translation movements.
For the comparable prior periods in 2022, additional adjustments included loss on early debt extinguishment and impairment charges.
Guidance, Outlook, and Management Commentary
Management utilizes non-GAAP measures to analyze operating performance, plan for future periods, and determine compensation. The company emphasizes that these measures exclude items that obscure underlying business trends, such as amortization and restructuring. The filing states that investors should consider these non-GAAP measures in conjunction with, not in lieu of, GAAP financial statements. No specific forward-looking guidance or risk factors are detailed within this specific 8-K text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2023 revenue, net income, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP results to understand the impact of excluded items like amortization and restructuring.
- Assess the impact of foreign currency translation on reported sales growth versus constant currency growth.
- Confirm the status of unusual litigation and contingent consideration adjustments mentioned in the non-GAAP adjustments.